Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC 704865) in Advanced, Poor Prognosis Carcinoid Patients

X
Trial Profile

Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC 704865) in Advanced, Poor Prognosis Carcinoid Patients

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Interferon alpha-2b (Primary) ; Octreotide
  • Indications Carcinoid tumour; Carcinoma; Colorectal cancer; Neuroendocrine tumours
  • Focus Therapeutic Use
  • Acronyms S0518
  • Most Recent Events

    • 02 Jun 2015 Primary endpoint has not been met. (Central-review based progression-free survival), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 27 Feb 2013 Planned end date changed from 1 Jan 2012 to 1 Jan 2015 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top